Results 81 to 90 of about 23,901 (228)
The responses using the identified denosumab regimes.
, 2012 (a) The active osteoclast using the identified denosumab regimes. (b) The bone volume using the identified denosumab regimes. (c) The MM-cell density using the identified denosumab regimes.
Yan Wang (15435), Bo Lin (116835)
core +1 more source
Systemic, Lifestyle and Environmental Modifying Factors in the Pathogenesis of Periodontitis
Journal of Periodontal Research, EarlyView.A variety of impacting factors in the pathogenesis of periodontitis exist, including systemic, lifestyle, and environmental factors. This review highlights the manifold mechanistic aspects of the link between the pathogenesis of periodontitis, addressing these numerous factors to supplement the long‐standing knowledge of the progression of the disease.
Sabine Elisabeth Groeger +5 more
wiley +1 more source
Osteoporosis in men: epidemiology and treatment with denosumab
, 2014 Kristel M Sidlauskas, Emily E Sutton, Michael A Biddle Albany College of Pharmacy and Health Sciences-Vermont Campus, Colchester, VT, USA Abstract: Osteoporosis is a major public health care concern.
Biddle MA, Sutton EE, Sidlauskas KM
core
Combined Effects of Romosozumab and Zoledronate on the Development of Osteonecrosis of the Jaw
Oral Diseases, EarlyView.ABSTRACT Objective This study aimed to assess the occurrence of medication‐related osteonecrosis of the jaw (MRONJ) in mice following the sequential administration of romosozumab and zoledronate and to confirm their inhibitory effects on osteoclast differentiation in vitro.
Hae‐Seo Park +5 more
wiley +1 more source
Biotechnology & Biotechnological EquipmentBulgarian real-world data on denosumab use for the prevention of skeletal-related events (SREs) associated with bone metastases (BM) from prostate cancer (PC) are lacking.
Antoaneta Tomova +4 more
doaj +1 more source
Case Reports in Oncological Medicine, 2018 Background. Denosumab has become the preferred agent over zolendronic acid to help prevent skeletal-related events in patients with metastatic bone disease and multiple myeloma because it is approved for use in those with kidney dysfunction.
Christina F. Marlow +3 more
doaj +1 more source
Oral Health Screening Prior to Oncological Treatment—The Helsinki Protocol
Oral Diseases, EarlyView.ABSTRACT Objectives Oncological treatments can have adverse effects on oral health and cause long‐term complications such as osteonecrosis. This retrospective study investigated the oral health of head and neck cancer patients before radiotherapy and patients with multiple myeloma, breast, prostate, lung, and kidney cancers before antiresorptive ...
Jemina Järvinen +4 more
wiley +1 more source
, 2010 David L Kendler1, Kenneth Shawn Davison21Prohealth Clinical Research, University of British Columbia, Vancouver, British Columbia, Canada; 2Department of Medicine, Division of Immunology and Rheumatology, Laval University, Quebec, CanadaAbstract ...
Kenneth Shawn Davison, David L Kendler
core
Oral Diseases, EarlyView.ABSTRACT Objectives To determine whether pretreatment radiomics can predict medication‐related osteonecrosis of the jaw (MRONJ). Methods Patients with mandibular MRONJ at Hiroshima University Hospital (2009–2024) who underwent MDCT before initiating bone resorption inhibitors were retrospectively identified. Records from 2009 to 2020 were also reviewed
Masaru Konishi
wiley +1 more source
Guillain-Barré Syndrome following Denosumab Administration in a Patient with Chronic Kidney Disease
Indian Journal of Kidney DiseasesGuillain-Barré syndrome (GBS) is an acute, immune-mediated polyradiculoneuropathy most often triggered by infections, but drug-induced cases are increasingly recognized.
Saurabh Puri +4 more
doaj +1 more source